Fate Therapeutics Reaches Analyst Target Price
February 22, 2018 at 09:27 AM EST
In recent trading, shares of Fate Therapeutics Inc (FATE) have crossed above the average analyst 12-month target price of $9.40, changing hands for $10.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..